Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology

Journal of the Advanced Practitioner in Oncology
doi 10.6004/jadpro.2018.9.7.2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

Onboarding for Advanced Practice Providers

HPB
HepatologyGastroenterology
2019English

Barriers to Oncology Biosimilars Uptake in the United States

Oncologist
Cancer ResearchMedicineOncology
2018English

Reply to ‘Biosimilars: A Position Paper of the European Society for Medical Oncology, With Particular Reference to Oncology Prescribers’

ESMO Open
Cancer ResearchOncology
2017English

Training Advanced Practice Providers to Collect Functional Outcomes After Fragility Fractures

Geriatric Orthopaedic Surgery & Rehabilitation
2015English

Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Canadian Public Reimbursement of Biosimilars (Referred to as Subsequent Entry Biologics – Sebs – In Canada), an Update

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Core Competencies in Cancer Genetics for Advanced Practice Oncology Nurses

Oncology Nursing Forum
Oncology
2002English

Biosimilars: Barriers and Opportunities to Market Access in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy